Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Elcelyx Therapeutics
San Diego, California, United Stateselcelyx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Elcelyx’s lead candidate, Metformin DR, demonstrated statistically significant reductions in HbA1c and fasting plasma glucose compared to placebo in a large Phase IIb trial involving patients with type 2 diabetes. The product was well tolerated and showed a favorable gastrointestinal side effect profile. Its unique mechanism—targeting drug delivery to the lower small intestine—enables effective glucose lowering with minimal systemic exposure, making it especially promising for patients with renal impairment or those intolerant to standard metformin.
- Therapeutic areas
- EndocrinologyMetabolic DisordersNephrology
- Modalities
- Small molecules (notably metformin formulations)Gut Sensory Modulators
- Industry
- Biotech
Beyond the preview
Go deeper on Elcelyx Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elcelyx Therapeutics.